Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gaël Ensergueix

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Nephrologie & Therapeutique|April 3, 2018
[Ifosphamide nephrotoxicity]Gaël Ensergueix, Alexandre Karras
Therapie|August 30, 2020
Patient's therapeutic education on renin-angiotensin system inhibitors could limit iatrogenic acute kidney injuries. The RASIzen studyCharles Verney, Blueberry Pierrel, Arnaud Le Flécher, et al.
Clinical Kidney Journal|September 8, 2020
Ifosfamide nephrotoxicity in adult patientsGaël Ensergueix, Nicolas Pallet, Dominique Joly, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Nephrologie & Therapeutique|April 3, 2018
[Ifosphamide nephrotoxicity]Gaël Ensergueix, Alexandre Karras
Therapie|August 30, 2020
Patient's therapeutic education on renin-angiotensin system inhibitors could limit iatrogenic acute kidney injuries. The RASIzen studyCharles Verney, Blueberry Pierrel, Arnaud Le Flécher, et al.
Clinical Kidney Journal|September 8, 2020
Ifosfamide nephrotoxicity in adult patientsGaël Ensergueix, Nicolas Pallet, Dominique Joly, et al.
Pageof 1